Ronald L Shazer Net Worth

The estimated Net Worth of Ronald L Shazer is at least $7.53 Tisíc dollars as of 3 June 2016. Ronald Shazer owns over 1,003 units of TRACON Pharmaceuticals Inc stock worth over $23 and over the last 9 years Ronald sold TCON stock worth over $7,502.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ronald Shazer TCON stock SEC Form 4 insiders trading

Ronald has made over 1 trades of the TRACON Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Ronald sold 1,003 units of TCON stock worth $7,502 on 3 June 2016.

The largest trade Ronald's ever made was selling 1,003 units of TRACON Pharmaceuticals Inc stock on 3 June 2016 worth over $7,502. On average, Ronald trades about 502 units every 0 days since 2015. As of 3 June 2016 Ronald still owns at least 335 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of Ronald Shazer stock trades at the bottom of the page.

What's Ronald Shazer's mailing address?

Ronald's mailing address filed with the SEC is C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE. 700, SAN DIEGO, CA, 92122.

Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.

What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Complete history of Ronald Shazer stock trades at TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Charles Theuer,
  President, Chief Executive Officer, Director
• Dr. Charles P. Theuer M.D., Ph.D.,
  CEO, Pres & Director
• Mark Wiggins,
  Chief Business Officer
• Mark C. Wiggins M.B.A.,
  Chief Bus. Officer
• Scott Brown,
  Chief Accounting Officer
• Scott B. Brown CPA, M.S.,
  Chief Financial Officer
• Suzy Benedict,
  Executive Vice President - Regulatory Affairs
• Stephen Worland,
  Independent Director
• J. Rainer Twiford,
  Independent Director
• Martin Mattingly,
  Independent Director
• William LaRue,
  Independent Director
• Saundra Pelletier,
  Director
• Bonne Adams,
  Executive Vice President - Clinical Operations
• Dr. Brenda Marczi Pharm.D., Pharmd Mba,
  Sr. VP of Regulatory Affairs
• Ya Huang,
  Exec. Director of Statistical Programming
• Bonne Adams,
  Exec. VP of Clinical Operations
• Dr. James L. Freddo,
  Chief Medical Officer
• Shahe Garabedian,
  Sr. VP & Head of Quality Assurance
• Ravi Nea Partners 14, L.P.N...,
  
• Peter W.Nea Partners 14, L....,
  
• Scott Dnea Partners 14, L.P...,
  
• Patrick Jnea Partners 14, L...,
  
• David Mnea Partners 14, L.P...,
  
• Anthony A. Jr.Nea Partners ...,
  
• Forestnea Partners 14, L.P....,
  
• Peter Jnea Partners 14, L.P...,
  
• M Jamesnea Partners 14, L.P...,
  
• Capital, Llc Ikarian Health...,
  
• Patricia L Bitar,
  CFO
• Forest Baskett,
  10% owner
• Patrick J Kerins,
  10% owner
• H Casey Logan,
  Chief Business Officer
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Tracon Investment Fund Ii, ...,
  
• Paul Edward Walker,
  Director
• Ronald L Shazer,
  Chief Medical Officer
• Krishna Kittu Kolluri,
  10% owner
• Ravi Viswanathan,
  10% owner
• Theodore T Wang,
  Director
• Cross Border Opportunities ...,
  
• Cross Border Opportunities ...,
  
• Harry R Weller,
  10% owner
• Enterprise Associates 14, L...,
  
• Ryan D Drant,
  10% owner
• Super V3 Investment Limited...,
  10% owner
• Management Inc. Opaleye,
  10% owner
• Capital, Llc Ikarian Health...,
  
• Lisa Johnson Pratt,
  Director
• Carol C. Lam,
  Director